Researcher
Anneleen Lintermans
- Disciplines:Gynaecology and obstetrics, Nursing, Endocrinology and metabolic diseases
Affiliations
- Gynaecological Oncology (Division)
Member
From1 Jan 2012 → 30 Sep 2014
Projects
1 - 1 of 1
- The etiology of the aromatase inhibitor-induced musculoskeletal syndrome in breast cancer patientsFrom25 Jan 2011 → 30 Sep 2014Funding: Private funding of national origin - undefined
Publications
1 - 10 of 17
- Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients(2016)
Authors: Anneleen Lintermans, Kathleen Van Asten, Lynn Jongen, Annouschka Laenen, Johan Verhaeghe, Dirk Vanderschueren, Diether Lambrechts, Patrick Neven
Pages: 31 - 6 - Genetic variant in the OPG gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients(2016)
Authors: Anneleen Lintermans, Kathleen Van Asten, Lynn Jongen, Annouschka Laenen, Johan Verhaeghe, Dirk Vanderschueren, Diether Lambrechts, Patrick Neven
Pages: 31 - 36 - Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens(2014)
Authors: Anneleen Lintermans, Dirk Vanderschueren, Johan Verhaeghe, Kathleen Van Asten, Annouschka Laenen, Robert Paridaens, Jaak Billen, Steven Pauwels, Pieter Vermeersch, Hans Wildiers, et al.
Pages: 2925 - 2931 - A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI(2014)
Authors: Anneleen Lintermans, Kathleen Van Asten, Hans Wildiers, Annouschka Laenen, Robert Paridaens, Caroline Weltens, Johan Verhaeghe, Dirk Vanderschueren, Ann Smeets, Erik Van Limbergen, et al.
Pages: 109 - 116 - Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study(2014)
Authors: Patrick Neven, Anneleen Lintermans, Gert Bellen
Pages: 371 - 9 - Aromatase inhibitors in the breast cancer clinic: focus on exemestane(2014)
Authors: Kathleen Van Asten, Patrick Neven, Anneleen Lintermans, Hans Wildiers, Robert Paridaens
Pages: R31 - R49 - Need for Estradiol Assays With a Lower Functional Sensitivity in Clinical Studies Examining Postmenopausal Women Treated With Aromatase Inhibitors(2013)
Authors: Steven Pauwels, Anneleen Lintermans, Patrick Neven, Johan Verhaeghe, Jaak Billen, Dirk Vanderschueren, Pieter Vermeersch
Pages: 509 - 509 - Sensitive routine liquid chromatography-tandem mass spectrometry method for serum estradiol and estrone without derivatization(2013)
Authors: Steven Pauwels, Leen Antonio, Anneleen Lintermans, Patrick Neven, Frank Claessens, Brigitte Decallonne, Jaak Billen, Dirk Vanderschueren, Pieter Vermeersch
Pages: 8569 - 77 - Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data(2013)
Authors: Anneleen Lintermans, Annouschka Laenen, Ben Van Calster, Steven Pans, Johan Verhaeghe, Rene Westhovens, Hans Wildiers, Robert Paridaens, Anne-Sophie Dieudonné, Karin Leunen, et al.
Pages: 350 - 5 - Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data(2013)
Authors: Anneleen Lintermans, Annouschka Laenen, Ben Van Calster, Steven Pans, Johan Verhaeghe, Rene Westhovens, Hans Wildiers, Robert Paridaens, Anne-Sophie Dieudonné, Karin Leunen, et al.
Pages: 350 - 5